Evidence map›Paper›PMID 39428527›Full record

ArticleInternal medicine (Tokyo, Japan)2025

KL-6 as a Tumor Marker of Primary Peritoneal Cancer in Patients with Connective Tissue Diseases.

Takao Nagashima, Keisuke Saito, Yoshifumi Takahashi, Kojiro Sato

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Takao NagashimaDivision of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University, Japan.
Keisuke SaitoDivision of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University, Japan.
Yoshifumi TakahashiDepartment of Gynecology and Obstetrics, Jichi Medical University, Japan.
Kojiro SatoDivision of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We herein report two patients with connective tissue disease who developed primary peritoneal cancer (PPC). Serum Krebs von den Lungen-6 (KL-6) levels increased when PPC was diagnosed, and these levels were correlated with the treatment and worsening of PPC in both cases. In one patient with systemic sclerosis, serum KL-6 levels increased despite stable interstitial lung disease (ILD), leading to a diagnosis of PPC. In the other patient with dermatomyositis and no ILD, PPC was diagnosed with elevated KL-6 levels four months post-treatment, without ILD development. Clinicians should be reminded that KL-6 is a tumor marker in various cancers.

Indexed as

Biomarkers, TumorConnective Tissue DiseasesMucin-1Peritoneal NeoplasmsAgedFemaleHumansMiddle AgedBiomarkers, TumorMUC1 protein, humanMucin-1dermatomyositisinterstitial lung diseaseovarian cancerperitoneal cancersystemic sclerosis

Identifiers

PMID39428527
PMCPMC12222902

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.